Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $30.00 at Cantor Fitzgerald

Capricor Therapeutics (NASDAQ:CAPR) had its price target raised by Cantor Fitzgerald from $25.00 to $30.00 in a research report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Piper Sandler initiated coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.04 during midday trading on Thursday, reaching $18.45. The company’s stock had a trading volume of 737,408 shares, compared to its average volume of 1,146,514. Capricor Therapeutics has a fifty-two week low of $2.87 and a fifty-two week high of $23.40. The company has a market cap of $837.81 million, a P/E ratio of -17.44 and a beta of 4.00. The business’s 50 day moving average price is $14.63 and its two-hundred day moving average price is $8.29.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 65.21 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics in the first quarter valued at $40,000. Main Street Financial Solutions LLC lifted its holdings in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in Capricor Therapeutics during the third quarter worth about $133,000. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the second quarter worth about $147,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics in the third quarter valued at approximately $161,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.